This evidence suggests that modern GLP-1 therapy outperforms older stimulant-based approaches, even as monotherapy
Your pharmacist can advise whether any interactions suggest separating your GLP-1 injection from other treatments
This delay came at an inopportune time as Tresiba was in the market barely a year before Eli Lilly & Boehringer Ingelheims biosimilar Basaglar launched last December, while Xultophy entered the market with physicians having just over a year of treatment experience with insulin degludec (Tresiba), one of its two key components (along with liraglutide)
Building research on the most current combination logic
While tirzepatide does not directly affect these antibodies, some research suggests that significant weight loss can reduce systemic inflammation, which may secondarily reduce antibody levels in some patients
Oral semaglutide is soon to come to the market and will be useful for people with type 2 diabetes who are averse to injections and are needle phobic